CAVEI updated its recommendations on the second booster dose of the COVID-19 vaccine:
CAVEI supports the MoH strategy of offering a second booster dose to people with immunosuppression, health workers and residents and workers of ELEAM with COVID-19 vaccine preferably based on messenger RNA and with 16 weeks of separation of the first vaccination booster against SARS-CoV-2. This in consideration of the objectives of the COVID-19 vaccination campaign to prevent COVID-19 morbidity and mortality in higher risk groups.
CAVEI recommends a second booster vaccination for the general population. The second booster dose in the general population should preferably be with an mRNA vaccine and 16 weeks apart from the first vaccination booster against SARS-CoV-2.
Reinforce for the population to complete primary schemes and first booster dose against SARS-CoV-2.
CAVEI recommends the simultaneous administration of vaccines against influenza and SARS-CoV-2 in people aged 3 years and older.
Co-administration of influenza virus and SARS-CoV-2 vaccines must be in anatomically different sites to avoid potentiation of non-serious local adverse reactions.